1.1050
25-11月-24 10:27:01
15 分の遅延
株式
+0.0250
+2.31%
本日の幅
1.0600 - 1.1200
ISIN
N/A
ソース
NASDAQ
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
12 1 2021 06:05:00 提供 Nasdaq GlobeNewswire
Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering
06 1 2021 06:05:00 提供 Nasdaq GlobeNewswire